BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fritsche E, Volk H, Reinke P, Abou-el-enein M. Toward an Optimized Process for Clinical Manufacturing of CAR-Treg Cell Therapy. Trends in Biotechnology 2020;38:1099-112. [DOI: 10.1016/j.tibtech.2019.12.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 26.0] [Reference Citation Analysis]
Number Citing Articles
1 Mikami N, Kawakami R, Sakaguchi S. New Treg cell-based therapies of autoimmune diseases: towards antigen-specific immune suppression. Curr Opin Immunol 2020;67:36-41. [PMID: 32827951 DOI: 10.1016/j.coi.2020.07.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
2 Mansourabadi AH, Mohamed Khosroshahi L, Noorbakhsh F, Amirzargar A. Cell therapy in transplantation: A comprehensive review of the current applications of cell therapy in transplant patients with the focus on Tregs, CAR Tregs, and Mesenchymal stem cells. Int Immunopharmacol 2021;97:107669. [PMID: 33965760 DOI: 10.1016/j.intimp.2021.107669] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hoogduijn MJ, Issa F, Casiraghi F, Reinders MEJ. Cellular therapies in organ transplantation. Transpl Int 2021;34:233-44. [PMID: 33207013 DOI: 10.1111/tri.13789] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
4 Romano M, Sen M, Scottà C, Alhabbab RY, Rico-Armada A, Lechler RI, Burch M, Lombardi G. Isolation and expansion of thymus-derived regulatory T cells for use in pediatric heart transplant patients. Eur J Immunol 2021;51:2086-92. [PMID: 33949684 DOI: 10.1002/eji.202048949] [Reference Citation Analysis]
5 Pinte L, Cunningham A, Trébéden-Negre H, Nikiforow S, Ritz J. Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy. Front Immunol 2020;11:608485. [PMID: 33658994 DOI: 10.3389/fimmu.2020.608485] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Mohseni YR, Tung SL, Dudreuilh C, Lechler RI, Fruhwirth GO, Lombardi G. The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology. Front Immunol 2020;11:1608. [PMID: 32793236 DOI: 10.3389/fimmu.2020.01608] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
7 Bettini M, Bettini ML. Function, Failure, and the Future Potential of Tregs in Type 1 Diabetes. Diabetes 2021;70:1211-9. [PMID: 34016597 DOI: 10.2337/dbi18-0058] [Reference Citation Analysis]
8 Reading JL, Roobrouck VD, Hull CM, Becker PD, Beyens J, Valentin-Torres A, Boardman D, Lamperti EN, Stubblefield S, Lombardi G, Deans R, Ting AE, Tree T. Augmented Expansion of Treg Cells From Healthy and Autoimmune Subjects via Adult Progenitor Cell Co-Culture. Front Immunol 2021;12:716606. [PMID: 34539651 DOI: 10.3389/fimmu.2021.716606] [Reference Citation Analysis]
9 Hefazi M, Bolivar-Wagers S, Blazar BR. Regulatory T Cell Therapy of Graft-versus-Host Disease: Advances and Challenges. Int J Mol Sci 2021;22:9676. [PMID: 34575843 DOI: 10.3390/ijms22189676] [Reference Citation Analysis]
10 Sebe A, Anliker B, Rau J, Renner M. [Genetically modified regulatory T cells: therapeutic concepts and regulatory aspects]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2020;63:1403-11. [PMID: 33067665 DOI: 10.1007/s00103-020-03230-8] [Reference Citation Analysis]
11 Roemhild A, Otto NM, Moll G, Abou-El-Enein M, Kaiser D, Bold G, Schachtner T, Choi M, Oellinger R, Landwehr-Kenzel S, Juerchott K, Sawitzki B, Giesler C, Sefrin A, Beier C, Wagner DL, Schlickeiser S, Streitz M, Schmueck-Henneresse M, Amini L, Stervbo U, Babel N, Volk HD, Reinke P. Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial. BMJ 2020;371:m3734. [PMID: 33087345 DOI: 10.1136/bmj.m3734] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 22.0] [Reference Citation Analysis]
12 Labbé RP, Vessillier S, Rafiq QA. Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives. Viruses 2021;13:1528. [PMID: 34452392 DOI: 10.3390/v13081528] [Reference Citation Analysis]
13 Alzhrani A, Bottomley M, Wood K, Hester J, Issa F. Identification, selection, and expansion of non-gene modified alloantigen-reactive Tregs for clinical therapeutic use. Cell Immunol 2020;357:104214. [PMID: 32977154 DOI: 10.1016/j.cellimm.2020.104214] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
14 Wang Y, Qiu T, Liang S, Toumi M. An overview of cell and gene therapy development in China. Hum Gene Ther 2021. [PMID: 34235966 DOI: 10.1089/hum.2021.126] [Reference Citation Analysis]
15 Vimond N, Lasselin J, Anegon I, Guillonneau C, Bézie S. Genetic engineering of human and mouse CD4+ and CD8+ Tregs using lentiviral vectors encoding chimeric antigen receptors. Mol Ther Methods Clin Dev 2021;20:69-85. [PMID: 33376756 DOI: 10.1016/j.omtm.2020.11.008] [Reference Citation Analysis]
16 Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer 2021;21:145-61. [PMID: 33483715 DOI: 10.1038/s41568-020-00323-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 25.0] [Reference Citation Analysis]
17 Abou-El-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P, Till BG, Bauer G, Savoldo B. Scalable Manufacturing of CAR T cells for Cancer Immunotherapy. Blood Cancer Discov 2021;2:408-22. [PMID: 34568831 DOI: 10.1158/2643-3230.bcd-21-0084] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Elsallab M, Bravery CA, Kurtz A, Abou-El-Enein M. Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals. Mol Ther Methods Clin Dev 2020;18:269-79. [PMID: 32637456 DOI: 10.1016/j.omtm.2020.05.035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
19 Horst AK, Kumashie KG, Neumann K, Diehl L, Tiegs G. Antigen presentation, autoantibody production, and therapeutic targets in autoimmune liver disease. Cell Mol Immunol 2021;18:92-111. [PMID: 33110250 DOI: 10.1038/s41423-020-00568-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
20 Vucinic V, Quaiser A, Lückemeier P, Fricke S, Platzbecker U, Koehl U. Production and Application of CAR T Cells: Current and Future Role of Europe. Front Med (Lausanne) 2021;8:713401. [PMID: 34490302 DOI: 10.3389/fmed.2021.713401] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]